CIK 0001346830
- Non-accelerated filer
- Smaller reporting company
Tvardi Therapeutics, Inc.
Sign in to watch- Ticker
- TVRD
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 713-489-8654
- Business address
- 3 SUGAR CREEK CTR. BLVD., STE 525, SUGAR LAND, TX, 77478
- Former names
- Cara Therapeutics, Inc., Cara Therapeutics Inc
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-08-02 | Boudreau Helen M Director | Grant or award · Stock Option (Right to Buy) | +155,747 | 155,747 | ||
| 2023-06-23 | Terrillion Scott Sec'y; Chief Compliance & G.C. | Sale 10b5-1 | −2,483 | $3.51 | $9K | 88,563 |
| 2023-06-23 | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Sale 10b5-1 | −2,993 | $3.51 | $11K | 153,747 |
| 2023-06-23 | Goncalves Joana Chief Medical Officer | Sale 10b5-1 | −2,723 | $3.51 | $10K | 53,681 |
| 2023-06-01 | von Moltke Lisa Director | Grant or award | +32,362 | 32,362 | ||
| 2023-06-01 | von Moltke Lisa Director | Grant or award · Stock Option (Right to Buy) | +44,961 | 44,961 | ||
| 2023-06-01 | Shiff Susan Ph.D. Director | Grant or award | +32,362 | 51,438 | ||
| 2023-06-01 | Shiff Susan Ph.D. Director | Grant or award · Stock Option (Right to Buy) | +44,961 | 44,961 | ||
| 2023-06-01 | Ives Jeffrey L. Director | Grant or award | +32,362 | 47,838 | ||
| 2023-06-01 | Ives Jeffrey L. Director | Grant or award · Stock Option (Right to Buy) | +44,961 | 44,961 | ||
| 2023-06-01 | BAINS HARRISON M JR Director | Grant or award | +32,362 | 57,438 | ||
| 2023-06-01 | BAINS HARRISON M JR Director | Grant or award · Stock Option (Right to Buy) | +44,961 | 44,961 | ||
| 2023-06-01 | VOGELBAUM MARTIN Director | Grant or award | +64,724 | 109,712 | ||
| 2023-06-01 | VOGELBAUM MARTIN Director | Grant or award · Stock Option (Right to Buy) | +89,923 | 89,923 | ||
| 2023-05-05 | Posner Christopher President and CEO | Sale 10b5-1 | −3,869 | $4.40 | $17K | 172,514 |
| 2023-04-04 | Terrillion Scott Sec'y; Chief Compliance & G.C. | Sale | −2,481 | $4.91 | $12K | 91,046 |
| 2023-04-04 | Goncalves Joana Chief Medical Officer | Sale | −2,481 | $4.91 | $12K | 56,404 |
| 2023-04-04 | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Sale | −2,733 | $4.91 | $13K | 156,740 |
| 2023-03-03 | Posner Christopher President and CEO | Sale | −5,987 | $9.71 | $58K | 176,383 |
| 2023-03-03 | Menzaghi Frederique Ph.D. Chief Scientific Off,SVP-R&D | Sale | −6,802 | $9.71 | $66K | 159,473 |
Page 5 of 7 · 123 trades